It's not much, but it's good to see HER-Vaxx got a mention in the slide pack and I think it's the first time I've seen HER-Vaxx and registrational trial used together:
It could simply be a case of them stating where HER-vaxx could go next however there is a chance we'll some more news about HER-Vaxx sooner or later, possibly after the next follow up report on the patients from the original ph2 which is due from next month onwards, or after we receive results from the nextHERIZON trial (I don't know how that's progressing though). Considering HER-Vaxx is not currently a priority, there may well be a suitor in late-stage licencing negotiations if they're now talking up the potential for a registrational trial.
Ann: Imugene Presentation to JPMorgan Healthcare Conference, page-31
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |